BTKis in CLL From EHA 2023

CME

Key Updates With BTK Inhibitors in CLL From EHA 2023

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: August 10, 2023

Expiration: August 09, 2024

Catherine C. Coombs
Catherine C. Coombs, MD, MS
Toby A Eyre
Toby A Eyre, MBChB, MD

Activity

Progress
1
Course Completed

References

  1. Acalabrutinib [prescribing information]. Wilmington, DE: AstraZeneca; 2022. 
  2. Burger J, Kim E, Sivina M, et al. Time-limited treatment with acalabrutinib plus obinutuzumab in treatment-naive chronic lymphocytic leukemia patients: early results of an ongoing phase 2 trial. Presented at: 2023 European Hematology Association Congress; June 8-11, 2023. Abstract P637.
  3. Langerbeins P, Zhang C, Robrecht S, et al. The CLL12 trial : ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. Blood. 2022;139:177-187. 
  4. Langerbeins P, Robrecht S, Nieper P, et al. Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage chronic lymphocytic leukemia (CLL): final results of the phase 3, double-blind, placebo-controlled CLL12 trial. Presented at: 2023 European Hematology Association Congress; June 8-11, 2023. Abstract S200.
  5. Stephens DM, Moseley A, Hill BT, et al. Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL study (SWOG S1925, NCT#04269902). J Clin Oncol. 2021;39(suppl 15):TPS7567.
  6. Brown JR, Desikan SP, Nguyen B, et al. Genomic evolution and resistance to pirtobrutinib in covalent BTK-inhibitor (CBTKI) pre-treated chronic lymphocytic leukemia (CLL) patients: results from the phase I/II BRUIN study. Presented at: 2023 European Hematology Association Congress; June 8-11, 2023. Abstract S146.
  7. Ghia P, Allan JN, Siddiqi T, et al. Fixed‐duration ibrutinib + venetoclax in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4‐y follow‐up from the FD cohort of the phase 2 CAPTIVATE study. Presented at: 2023 International Conference on Malignant Lymphoma; June 13-17, 2023. Abstract 155.
  8. Tedeschi A, Barr PM, Allan JN, et al. Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma: 4-year follow-up from the FD cohort of the phase 2 CAPTIVATE study. Presented at: 2023 European Hematology Association Congress; June 8-11, 2023. Abstract P617. 
  9. Al-Sawaf O, Zhang C, Robrecht S, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 5-year results of the randomized CLL14 study. Presented at: 2022 European Hematology Association Congress; June 9-12, 2022. Abstract S148.
  10. Kater AP, Owen C, Moreno C, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid. 2022;1:1-13. 
  11. Jain N, Keating M, Thompson P, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial. JAMA Oncol. 2021;7:1213-1219.
  12. Munir T, Shadman M, Robak T, et al. Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the sequoia study. Presented at: 2023 European Hematology Association Congress; June 8-11, 2023. Abstract P639.
  13. Shadman M, Munir T, Roback T, et al. Zanubrutinib (zanu) versus bendamustine + rituximab (BR) in patients (pts) with treatment‐naive (TN) CLL/SLL: extended follow‐up of the SEQUOIA study. Presented at: 2023 International Conference on Malignant Lymphoma; June 13-17, 2023. Abstract 154.
  14. Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23:1031-1043.